Defatted silkworm pupae meal as an alternative protein source for cattle.

Silkworm pupae meal (SWP) is a protein-rich by-product of the silk reeling industry, available in a significant quantity. However, there has been little and insignificant research into the use of SWP in ruminants to date. In this view, the present study was conducted in two phases to evaluate the effect of different inclusion levels of defatted silkworm pupae meal (DSWP) on rumen fermentation, microbial protein synthesis and nutrient utilisation in cattle fed on finger millet straw (FMS)-based diet. Four isonitrogenous concentrate mixtures (CM) were prepared with DSWP replacing soybean meal (SBM) protein at 0 (T0), 10 (T1), 20 (T2) and 30% (T3). In phase I, a rumen fermentation experiment was conducted in a 4 × 4 Latin square design using four crossbred steers to study the effect of different levels of DSWP on rumen fermentation. No significant difference (P > 0.05) was observed in rumen fermentation parameters such as pH, ammonia nitrogen (NH3-N) and total volatile fatty acids (VFA) among the experimental groups. In phase II, the digestibility trial was conducted in 20 crossbred cattle (311.2 ± 4.81 kg), which were divided into four experimental groups of five animals each in a completely randomised design to study the effect of different rations (T0, T1, T2, T3) on microbial protein synthesis and nutrient utilisation. The intake and digestibility of nutrients, excretion of urinary purine derivatives and microbial protein synthesis were not significantly different among the experimental groups. In addition, feeding DSWP revealed no significant (P > 0.05) change in the blood biochemical parameters of animals. Furthermore, at the same price as SBM, DSWP provides two units more crude protein. Therefore, the results of the present study indicated that DSWP can be incorporated into the ration of cattle up to 30% by replacing SBM without affecting rumen fermentation pattern and nutrient utilisation.

Exploring the SARS-Cov-2 Main Protease (Mpro) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19.

The unprecedented pandemic of COVID-19 caused by the novel strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engulfs millions of death worldwide. It has directly hit the socio-economic status of the affected countries. There are more than 219 countries badly affected by the COVID-19. There are no particular small molecule inhibitors to combat the dreadful virus. Many antivirals, antimalarials, antiparasitic, antibacterials, immunosuppressive antiinflammatory, and immune stimulatory agents have been repurposed for the treatment of COVID-19. But the exact mechanism of action of these drugs towards COVID-19 targets has not been experimented with yet. Under the effect of chemotherapeutics, the virus may change its genetic material and produces various strains, which are the main reasons behind the dreadful attack of COVID-19. The nuclear genetic components are composed of main protease and RNA-dependent RNA polymerase (RdRp) which are responsible for producing nascent virion and viral replication in the host cells. To explore the biochemical mechanisms of various small molecule inhibitors, structure-based drug design can be attempted utilizing NMR crystallography. The process identifies and validates the target protein involved in the disease pathogenesis by the binding of a chemical ligand at a well-defined pocket on the protein surface. In this way, the mode of binding of the ligands inside the target cavity can be predicted for the design of potent SARS-CoV-2 inhibitors.